dm+d

Unassigned

New Medicines

EGFR mutated non-small cell lung cancer (NSCLC) - second- or third-line after failure of EGFR TKI therapy

Information

New molecular entity
Daiichi Sankyo
Daiichi Sankyo

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

An antibody-drug conjugate (ADC) comprising an anti-HER3 mAb linked to a topoisomerase I inhibitor, given every 3 weeks
There are around 48,500 new lung cancer cases in the UK every year. Since the early 1990s, lung cancer incidence rates have decreased by around a tenth (9%) in the UK. Rates in females have increased by around a third (32%), and rates in males have decreased by around a third (34%). Incidence rates for lung cancer are projected to fall by 7% in the UK between 2014 and 2035, to 88 cases per 100,000 people by 2035 [1].
EGFR mutated non-small cell lung cancer (NSCLC) - second- or third-line after failure of EGFR TKI therapy
Intravenous